As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit incentives and small market size as the most important obstacles to…

We investigate the importance of “what”-flexibility on top of “where”- and “when”-flexibility for alternative emission control schemes that prescribe long-term temperature targets and eventually impose…